Header Logo

Connection

Igor Koralnik to Leukoencephalopathy, Progressive Multifocal

Back to Details
This is a "connection" page, showing publications Igor Koralnik has written about Leukoencephalopathy, Progressive Multifocal.
Igor Koralnik
Connection Strength
22.844
Leukoencephalopathy, Progressive Multifocal
  1. Progressive multifocal leukoencephalopathy in Zambia is caused by JC virus with prototype regulatory region. J Neurovirol. 2019 08; 25(4):475-479.
    View in: PubMed
    Score: 0.571
  2. JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy. J Neurovirol. 2019 08; 25(4):520-524.
    View in: PubMed
    Score: 0.570
  3. Can Immune Checkpoint Inhibitors Keep JC Virus in Check? N Engl J Med. 2019 04 25; 380(17):1667-1668.
    View in: PubMed
    Score: 0.569
  4. ViroFind: A novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients. PLoS One. 2018; 13(1):e0186945.
    View in: PubMed
    Score: 0.523
  5. PML-IRIS in an HIV-2-infected patient presenting as Bell's palsy. J Neurovirol. 2017 10; 23(5):789-792.
    View in: PubMed
    Score: 0.508
  6. Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. J Neurovirol. 2016 08; 22(4):464-71.
    View in: PubMed
    Score: 0.452
  7. Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PML. J Acquir Immune Defic Syndr. 2015 Dec 01; 70(4):357-61.
    View in: PubMed
    Score: 0.451
  8. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol. 2015 Oct; 78(4):501-14.
    View in: PubMed
    Score: 0.440
  9. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology. 2014 Aug 19; 83(8):727-32.
    View in: PubMed
    Score: 0.410
  10. Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol. 2014 May; 75(5):659-69.
    View in: PubMed
    Score: 0.404
  11. Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation. Biol Blood Marrow Transplant. 2014 Jul; 20(7):992-9.
    View in: PubMed
    Score: 0.401
  12. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol. 2013 Nov; 72(11):1043-51.
    View in: PubMed
    Score: 0.390
  13. Gone over to the dark side: Natalizumab-associated JC virus infection of neurons in cerebellar gray matter. Ann Neurol. 2013 Oct; 74(4):503-5.
    View in: PubMed
    Score: 0.388
  14. Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome. Brain. 2013 Nov; 136(Pt 11):3441-50.
    View in: PubMed
    Score: 0.388
  15. ABO blood groups and risk for progressive multifocal leukoencephalopathy. JAMA Neurol. 2013 Oct; 70(10):1331-2.
    View in: PubMed
    Score: 0.388
  16. Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis. Neuropathology. 2014 Feb; 34(1):39-44.
    View in: PubMed
    Score: 0.378
  17. Detection of JC virus-specific immune responses in a novel humanized mouse model. PLoS One. 2013; 8(5):e64313.
    View in: PubMed
    Score: 0.378
  18. A game of viral hide and seek: miliary PML masquerading as EBV encephalitis in an HIV+ patient. Clin Neurol Neurosurg. 2013 Sep; 115(9):1861-3.
    View in: PubMed
    Score: 0.374
  19. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 Nov 20; 79(21):2160; author reply 2160.
    View in: PubMed
    Score: 0.365
  20. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol. 2013 Jan 24; 8:189-215.
    View in: PubMed
    Score: 0.363
  21. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology. 2012 Sep 04; 79(10):1041-8.
    View in: PubMed
    Score: 0.359
  22. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):244-8.
    View in: PubMed
    Score: 0.356
  23. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One. 2012; 7(4):e35793.
    View in: PubMed
    Score: 0.351
  24. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 May 01; 78(18):1390-3.
    View in: PubMed
    Score: 0.351
  25. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology. 2012 Jan 03; 78(1):73; author response 73-4.
    View in: PubMed
    Score: 0.344
  26. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2012 Jan; 71(1):54-65.
    View in: PubMed
    Score: 0.344
  27. Hidden in plain view: emergence of progressive multifocal leukoencephalopathy after treatment of CNS toxoplasmosis. Acta Neurol Belg. 2011 Sep; 111(3):217-9.
    View in: PubMed
    Score: 0.336
  28. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis. 2011 Oct; 53(7):711-5.
    View in: PubMed
    Score: 0.335
  29. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol. 2011 Jul; 85(14):7256-63.
    View in: PubMed
    Score: 0.328
  30. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010 Nov; 81(11):1288-91.
    View in: PubMed
    Score: 0.312
  31. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010 Apr; 9(4):425-37.
    View in: PubMed
    Score: 0.304
  32. Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. J Neurovirol. 2010 Feb; 16(1):41-7.
    View in: PubMed
    Score: 0.301
  33. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009 Nov 10; 73(19):1551-8.
    View in: PubMed
    Score: 0.296
  34. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):247-54.
    View in: PubMed
    Score: 0.295
  35. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009 Sep 10; 361(11):1067-74.
    View in: PubMed
    Score: 0.293
  36. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009 Jun; 65(6):742-8.
    View in: PubMed
    Score: 0.287
  37. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2009 Jan; 68(1):15-25.
    View in: PubMed
    Score: 0.279
  38. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology. 2009 Jan 20; 383(2):173-7.
    View in: PubMed
    Score: 0.278
  39. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol. 2008 Oct; 14(5):455-8.
    View in: PubMed
    Score: 0.276
  40. Productive simian virus 40 infection of neurons in immunosuppressed Rhesus monkeys. J Neuropathol Exp Neurol. 2008 Aug; 67(8):784-92.
    View in: PubMed
    Score: 0.271
  41. BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol. 2008 Jun; 42(2):198-202.
    View in: PubMed
    Score: 0.264
  42. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol. 2007 Oct; 13(5):474-6.
    View in: PubMed
    Score: 0.256
  43. Remission of progressive multifocal leukoencephalopathy and primary central nervous system lymphoma in an HIV-infected patient. Eur J Neurol. 2007 Jun; 14(6):598-602.
    View in: PubMed
    Score: 0.250
  44. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol. 2007 Apr; 81(7):3361-8.
    View in: PubMed
    Score: 0.244
  45. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol. 2006 Aug; 60(2):162-73.
    View in: PubMed
    Score: 0.236
  46. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J Neurovirol. 2006 Apr; 12(2):116-28.
    View in: PubMed
    Score: 0.231
  47. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006 Jan 24; 66(2):262-4.
    View in: PubMed
    Score: 0.228
  48. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS. 2005 Dec 02; 19(18):2069-76.
    View in: PubMed
    Score: 0.225
  49. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis. 2005 Aug 01; 41(3):417-9.
    View in: PubMed
    Score: 0.220
  50. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med. 2005 Jul 28; 353(4):414-6.
    View in: PubMed
    Score: 0.218
  51. Rearrangement of simian virus 40 regulatory region is not required for induction of progressive multifocal leukoencephalopathy in immunosuppressed rhesus monkeys. J Virol. 2005 Feb; 79(3):1361-6.
    View in: PubMed
    Score: 0.213
  52. Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation. J Neurovirol. 2005 Feb; 11(1):46-50.
    View in: PubMed
    Score: 0.213
  53. New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol. 2005; 11 Suppl 3:52-7.
    View in: PubMed
    Score: 0.212
  54. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology. 2004 Sep 14; 63(5):897-900.
    View in: PubMed
    Score: 0.207
  55. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004 Sep; 127(Pt 9):1970-8.
    View in: PubMed
    Score: 0.204
  56. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med. 2004 Apr 29; 350(18):1882-93.
    View in: PubMed
    Score: 0.202
  57. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol. 2003 Nov; 77(22):11918-26.
    View in: PubMed
    Score: 0.195
  58. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology. 2003 Sep 23; 61(6):775-82.
    View in: PubMed
    Score: 0.194
  59. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol. 2003; 9 Suppl 1:25-31.
    View in: PubMed
    Score: 0.184
  60. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol. 2002 Dec; 8 Suppl 2:59-65.
    View in: PubMed
    Score: 0.183
  61. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol. 2002 Jan 01; 168(1):499-504.
    View in: PubMed
    Score: 0.172
  62. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells. Int J Mol Sci. 2021 Sep 10; 22(18).
    View in: PubMed
    Score: 0.168
  63. Advances in Treatment of Progressive Multifocal Leukoencephalopathy. Ann Neurol. 2021 12; 90(6):865-873.
    View in: PubMed
    Score: 0.168
  64. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol. 2001 Aug; 7(4):318-22.
    View in: PubMed
    Score: 0.167
  65. JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol. 2001 Jun; 75(12):5672-6.
    View in: PubMed
    Score: 0.165
  66. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021 06 01; 78(6):736-740.
    View in: PubMed
    Score: 0.165
  67. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol. 2001 Apr; 75(7):3483-7.
    View in: PubMed
    Score: 0.163
  68. Brainstem progressive multifocal leukoencephalopathy. Eur J Neurol. 2021 03; 28(3):1016-1021.
    View in: PubMed
    Score: 0.159
  69. Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):220-224.
    View in: PubMed
    Score: 0.147
  70. Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J Neurovirol. 1999 Aug; 5(4):430-5.
    View in: PubMed
    Score: 0.145
  71. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
    View in: PubMed
    Score: 0.142
  72. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology. 1999 Jan 15; 52(2):253-60.
    View in: PubMed
    Score: 0.140
  73. A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient. Transplantation. 2017 06; 101(6):1461-1467.
    View in: PubMed
    Score: 0.125
  74. JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. J Neurovirol. 2017 02; 23(1):141-146.
    View in: PubMed
    Score: 0.118
  75. Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. J Neurovirol. 2016 08; 22(4):541-5.
    View in: PubMed
    Score: 0.113
  76. JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. JAMA Neurol. 2014 Apr; 71(4):487-9.
    View in: PubMed
    Score: 0.100
  77. Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review. Pediatr Infect Dis J. 2014 Apr; 33(4):e99-105.
    View in: PubMed
    Score: 0.100
  78. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013 Apr 09; 80(15):1430-8.
    View in: PubMed
    Score: 0.094
  79. Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol. 2011 Oct; 17(5):500-3.
    View in: PubMed
    Score: 0.083
  80. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology. 2011 Jul 19; 77(3):297-9.
    View in: PubMed
    Score: 0.083
  81. Infrequent detection of KI, WU and MC polyomaviruses in immunosuppressed individuals with or without progressive multifocal leukoencephalopathy. PLoS One. 2011 Mar 16; 6(3):e16736.
    View in: PubMed
    Score: 0.081
  82. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009 Oct; 9(10):625-36.
    View in: PubMed
    Score: 0.073
  83. Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. J Clin Oncol. 2008 Aug 01; 26(22):3804-7.
    View in: PubMed
    Score: 0.068
  84. Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int Immunol. 2007 Sep; 19(9):1083-93.
    View in: PubMed
    Score: 0.063
  85. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007 Sep 01; 196(5):709-11.
    View in: PubMed
    Score: 0.063
  86. A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J Gen Virol. 2006 Sep; 87(Pt 9):2533-2537.
    View in: PubMed
    Score: 0.059
  87. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry. 2006 Sep; 77(9):1079-82.
    View in: PubMed
    Score: 0.059
  88. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005 Apr; 57(4):576-80.
    View in: PubMed
    Score: 0.054
  89. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol. 2004 Sep; 78(18):10206-10.
    View in: PubMed
    Score: 0.052
  90. Meningoencephalitis and demyelination are pathologic manifestations of primary polyomavirus infection in immunosuppressed rhesus monkeys. J Neuropathol Exp Neurol. 2004 Jul; 63(7):750-8.
    View in: PubMed
    Score: 0.051
  91. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2004 Jun; 17(3):365-70.
    View in: PubMed
    Score: 0.051
  92. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol. 2003; 9 Suppl 1:88-92.
    View in: PubMed
    Score: 0.046
  93. [Neurological complication of human immunodeficiency virus infection]. Presse Med. 1991 Jun 22; 20(24):1129-35.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.